Background: We conducted a phase I-II trial to assess the feasibility and activity of a combination chemotherapy regimen with etoposide, ifosfamide, cisplatin or carboplatin, and epirubicin in limited-disease (LD, stages I-IIIB) and extensivestage (ED, stage IV) small-cell lung cancer (SCLC).
Introduction
Despite the advent of increasingly aggressive multimodality protocols featuring chemotherapy [1] , maintenance chemotherapy [2] , chemoradiation [3, 4] , thoracic radiation therapy (TRT) [5] [6] [7] , prophylactic cranial irradiation (PCI) [8] , surgery [9] [10] , and a variety of innovative multi-modal protocols [11] [12] [13] , curative therapy remains available to only a minority of patients with LD SCLC, while treatment for ED SCLC is in most instances still palliative only [3, [14] [15] [16] . Until quite recently, LD SCLC patients could expect a median survival of 12-18 months, a response duration of 6-12 months, and a two-year survival of 15%-25% [14] [15] [16] . Corresponding figures for ED SCLC were 6-11 months, 3-6 months, and 0%-3% for two-year survival [14] [15] [16] .
Improved two-year survival rates of 43%-47% and five-year survival rates of 19%-26% have recently been reported in trials involving the concurrent use of TRT and chemotherapy based on cisplatin/etoposide [17, 18] . In addition, technical optimizations [19] , and the extension of these protocols to elderly patients [20] could contribute to a potential impact of concurrent radiochemotherapy on the survival of SCLC. However, these results were not yet available when our trial was initiated.
Chemotherapy dose intensification with hematopoietic growth-factor (HGF) support has been shown to improve response rates, but its effects on survival have been inconsistent [21] [22] [23] [24] [25] [26] . As a result, both the use of HGF [27, 28] and the concept of dose-intensity [29] [30] [31] [32] [33] remain the subjects of controversial debate. For more than 15 years, high-dose chemotherapy (HDC) with autologous bone marrow (ABMT), or peripheral blood stem-cell transplantation (PBSCT) in SCLC has been explored by groups in the United States, Poland, Switzerland, Austria, Japan, China, and other countries [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . Despite these efforts, the role of HDC with ABMT or PBSCT in SCLC, or subsets of patients with SCLC, has yet to be defined [50] [51] [52] .
The reasons for this are obvious; the entire current world literature on HDC in SCLC encompases little more than 350 treated patients; the median follow-up of most of the trials rarely exceeds two years; treatmentrelated morbidity and mortality, in particular in patients with ED SCLC, have been far from negligible, thereby restricting the use of HDC to academic tertiary care centers; lastly, treatment results, while often impressive with respect to response rates and short-term survival, have not yielded convincing evidence that the HDC approach in LD SCLC is superior, and have been disappointing in ED SCLC [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] .
In 1989 we began to investigate in selected patients the feasibility and activity of HGF-supported VIP-E SDC and VIC-E HDC followed by PBSCT in the context of a multi-modal approach in SCLC that included adjuvant thoracic radiation, prophylactic cranial irradiation, and surgery. After reporting initial results in 1997 [53] , and an interim follow-up report on the pilot cohort [54] , we now report the updated results of the entire cohort of 100 patients with a mature median follow-up of more than five years.
Patients and methods

Patient eligibility and characteristics
The enrollment period was 1989-1995. For participation, SCLC patients between 18 and 60 years of age were required to have an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0-3 and no evidence of significant organ dysfunction. One hundred patients entered the study (33 LD SCLC, 67 ED SCLC). The median age of the patients was 56 years (range 25-65); 87% were male and 13% female, and stage distribution in LD SCLC was as follows: I (9%), II (3%), IIIA (30%), IIIB (58%). 95% of patients were, or had been, active smokers (see Table 1 ). In this and the following sections we refer for details to our original publication [53] .
Treatment plan
Standard-dose chemotherapy (SDC) consisted of etoposide (500 mg/m 2 ), ifosfamide (4000 mg/m 2 ), cisplatin (50 mg/m 2 ), and epirubicin (50 mg/m 2 ) (VIP-E). The patients received two cycles of VIP-E at three-week intervals, and were treated for a maximum of four cycles (median three). Patients with CR or PR after VIP-E proceeded to highdose chemotherapy (HDC) if they met the eligibility criteria for this treatment (e.g., adequate PS and organ function). High-dose chemotherapy (HDC) was given three weeks after SDC at a cumulative dose of etoposide 1,500 mg/m 2 , ifosfamide 12,000 mg/m 2 , carboplatin 750 mg/m 2 , and epirubicin 150 mg/m 2 (VIC-E) with unpurged PBSCT 24 hours after completion of HDC. Surgical resection of the primary tumor before or after chemotherapy was performed whenever feasible. Thoracic radiation therapy (TRT) was given to all HDC patients, and to patients in PR or CR after SDC Prophylactic cranial irradiation (PCI) was added in CR patients.
Follow-up
One hundred patients were accrued from 1989 to 1995. Recruitment was stopped as of 31 December 1995; follow-up for this report was censored as of 1 December 1998. Time to relapse was defined as the last day of treatment to first documentation of recurrence or renewed progression. Survival was measured from end of therapy to date of death. Death of any cause was included in the survival evaluation. Patients still alive were censored on the last day of contact. None of the patients were lost to follow-up. The current median follow-up of all patients from time of therapy is 68 months (range 38-98). The median follow-up of the 14 patients still alive (all in CR) is 61 months (range . The mean durations of response and survival as stated in the text were calculated on the basis of the numerical mean of all evaluable patients. The median durations of response and survival in the figures were assessed according to the methods described by Kaplan-Meier [55] .
Results
Patient eligibility for high-dose chemotherapy
Fifty of sixty-seven ED patients were eligible for HDC, and thirty-nine of fifty continued SDC for a variety of reasons (poor PS, toxicity of SDC, and others). Of 28 of 33 LD patients eligible for HDC, 9 of 25 patients continued SDC. As a result only 11 of 50 (22%) and 19 of 28 (68%) of eligible ED and LD patients underwent HDC, respectively. Seventy percent of the patients received SDC only and 30% SDC plus HDC. In sum, 16% of ED patients, and 58% of LD patients underwent SDC and HDC. Differences between patients receiving SDC and HDC are shown in Table 2 . As a result of the more stringent selection criteria for HDC, the latter group includes younger patients with better responses to SDC and a better PS.
Surgical treatment
Six patients with LD-SCLC underwent surgery prior to SDC with four R o (complete) resections, and one Rj (microscopic residual tumor) and R 2 (macroscopic residual tumor) resection each. All four patients with stage I-II SCLC underwent R 0 -resection. Five patients with LD-SCLC underwent surgery after neo-adjuvant SDC (n = 4), or after HDC (n = 1); all had R 0 -resections. Of 10 patients with stage IIIA disease (denned by TNM criteria as T)N 2 , T 2 N 2 , or T 3 N 0 N 2 with no distant metastases), 2 had R o , 3 Ri, and 1 a R 2 -resection. Five patients with LD-SCLC underwent surgery after neoadjuvant SDC (four), or after HDC (one); all had R oresections. All patients received TRT regardless of their surgical status; TRT was given to the tumor site as defined by the pre-operative and pre-chemotherapy computed tomography scan of the chest. One patient with ED-SCLC had a R 0 -resection of a contralateral pulmonary metastasis after HDC; no other surgery was performed in patients with ED SCLC.
Radiation therapy
Patients with LD-SCLC underwent consolidation mediastinal TRT after completing either VIP-E SDC or VIC-E HDC. The interval between hospital release and initiation of radiation therapy was two to four weeks, depending on the extent of the physical or hematological rehabilitation. Radiation dose was 50 Gy, duration of treatment was five weeks, daily doses were 2 Gy given as a single fraction on weekdays only. Hyperfractioned radiation therapy was not given within this trial. Prophylactic whole brain irradiation was given concurrently with TRT to all LD-SCLC patients in CR after completing chemotherapy. Radiation dose was 30 Gy, duration of treatment was three weeks, daily doses were 2 Gy.
Response -standard-dose VIP-E
Excluding six patients already in surgical CR before therapy and two patients with toxic death after therapy, the overall response rate for SDC was 78%. Objective response rates (ORR) were 81% for LD, and 77% in ED; for details see Table 2 .
Response -high-dose VIC-E
All patients improved or maintained prior responses; details are shown in Table 4 . Ten (53%) patients had no evidence of tumor when entering HDC. Of these, three had Rn-resection prior to SDC, and three after neoadjuvant SDC; the remaining four patients went into CR by VIP-E SDC; for details see Table 3 . Months after SDC
Survival -standard-dose VIP-E
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Figure 1. Kaplan-Meier plots of overall survival (OS), relapse-free (RFS), and event-free survival (EFS) of SCLC patients after high-dose (HDC)
and standard-dose (SDC) chemotherapy. a Adjuvant patients and one toxic death excluded; one LD patient was in CR at autopsy, one LD patient died without assessment of response; the two ED patients with toxic death died in PR.
five-year survival in LD-SCLC excluding this favourable subset is 14%.
Survival -high-dose VIC-E
Thrity patients proceeded to HDC. Ten of nineteen (53%) LD SCLC patients have died, two of TRM, seven of relapse, one in CR of a SM at 85 months. Nine (47%) patients are alive in CR at 46+, 49+, 53+, 54+, 61+, 63+, 70+, 76+, and 80+ months. All 11 ED SCLC patients have died; 2 of TRM and 9 of relapsed SCLC. Median survival was 26 months in LD SCLC and 8 months in ED SCLC. Kaplan-Meier estimate of five-year survival -excluding the patient who succumbed to a secondary esophageal carcinoma -is 50% in LD SCLC (95% CI: 38%-62%). The last survivor having died after 26 months, five-year survival was 0% in the ED SCLC group. Figure 1 shows the Kaplan-Meier projections of survival in all four treatment groups. Survival in ED SCLC is given as event-free survival (EFS) since there were no SM in this cohort; however, TRM was included. Survival in LD SCLC is given as relapse-free survival (RFS); occurrence of (« = 4), and death from (n = 1) SM in this cohort has not been marked.
Six LD SCLC patients received R 0 -resections prior to any chemotherapy; three of these received SDC only, and three additional HDC. Five-year survival after HDC in LD SCLC excluding this favourable subset of patients is 33%.
Treatment of relapse
In addition to six patients who died of TRM, 80 of 81 relapse patients died of SCLC. Only one patient is currently alive with terminal PD. None of the patients experienced durable remissions after treatment for relapse, and no relapses were cured.
Secondary malignancies after standard-dose VIP-E
Two patients developed secondary malignancies (SM) after VIP-E SDC. Two patients treated only with VIP-E SDC developed a secondary NSCLC 40 and 47 months after initial diagnosis of LD SCLC; complete surgical resection of the secondary lung cancer was performed in both instances. Remarkably, both patients are in CR from either malignancy at an additional follow-up of 18+ and 40+ months. The rate of SM in all SCLC patients treated with VIP-E SDC was 2 of 70 (3%), the rate of SM in LD SCLC was 2 of 15 (13%), and the rate of SM in patients in CR > 2 years after SDC was 2 of 5 (40%).
Secondary malignancies after high-dose VIC-E
One patient developed secondary chronic myelogenous leukemia 28 months after HDC and PBSCT, and is currently in the first chronic phase of CML at 28+ months, and in CR of SCLC at 56+ months after HDC; the case has been described in greater detail elsewhere [56] . Another patient developed a secondary squamouscell carcinoma of the esophagus 78 months after HDC; he died of this cancer while in CR from SCLC 85 months after HDC. The rate of SM in all SCLC patients treated with VIC-E HDC was 2 of 30 (7%), the rate of SM in LD-SCLC was 2 of 19 (11%), and the rate among patients in CR from SCLC > 2 years after HDC was 2 of 10 (20%).
Discussion
The results of this trial with regard to the use of VIP-E SDC or VIC-E HDC in LD-SCLC and ED-SCLC can be separated into four categories:
1. VIP-E SDC treatment results in patients with ED-SCLC are characterised by marked toxicity and a 4% TRM. Despite good response rates, survival in this cohort was no better than that which is achievable with less toxic regimens. Therefore, the relatively low therapeutic index of VIP-E suggests that less aggressive palliative protocols should be favored in ED-SCLC. The Hoosier Oncology Group has published results on 40 ED patients treated with a VIP regimen similar to our VIP-E protocol. With a response rate of 71%, a TRM of 12.5%, and a median survival of 41 weeks, treatment outcomes were comparable to those in our 56-patient cohort. Whether VIP-E SDC could benefit the rare younger ED patient with good PS and a limited size and number of visceral metastases could not be determined within the limits of our trial. Certainly, VIP-E is not indicated in typical elderly ED patients with a poor PS and disseminated visceral and/or bone marrow disease.
2. With profound toxicity in all patients, an 18% TRM, and a disappointingly low median duration of response and survival, the results of VIC-E HDC discourage the use of this HDC protocol in ED SCLC. This is further supported by the observation that the patients in this cohort represented a select 16% subgroup of the most physically fit ED-SCLC patients with the most sensitive disease. These results may be of interest for comparison with outcomes of ongoing trials of HDC in ED-SCLC [33, 35, 36, 40, 41] , some of which use HDC protocols quite similar to our VIC-E HDC regimen; for example, three courses of VIC HDC are used in several studies [33, 40, 41] . Our results clearly differ from an American study reporting a 20% two-year progressionfree survival after HDC for ED-SCLC [36] . To our knowledge, there have been no other data indicating a significant benefit from instituting HDC in ED-SCLC.
3. With no TRM, less toxicity, and a five-year survival of 36% LD-SCLC patients fared relatively well with VIP-E SDC. However, of the five patients remaining in CR in this group, three had curative resections prior to chemotherapy. Therefore, the question of whether an adequate number of VIP-E treatment cycles, combined with thoracic irradiation and, if feasible, surgery, may in itself be an effective treatment concept for LD-SCLC cannot be answered without further studies in larger patient populations. A German multicenter study was initiated in 1997 to compare this approach to the use of HDC VIC-E in LD SCLC [54] .
4. Treatment toxicity with VIC-E HDC was moderate in most patients with LD-SCLC. However, two toxic deaths in this group add up to a TRM of 18%, which is unacceptable in an era when HDC-related mortality has declined to 2%-5%. Improved supportive care is of predominant concern for this subgroup, while treatment activity is good. More will be learned about the value of this approach as results from the German multicenter trial become available [54] . Comparing our results to those of other HDC trials in LD-SCLC, the 50% fiveyear disease-free survival (DFS) after VIC-C HDC is in accordance with reported DFS rates of 40%-56%, most of which were, however, measured with shorter followup intervals of 12-24 months . As in our SDC treatment cohort, prior surgical resections may have contributed to the outcome in this subgroup although the literature on the role of surgery in SCLC does not indicate that operative interventions are responsible for significant improvements in outcome [9, 10] .
In sum, neither our trial, nor the published evidence on the use of HGF [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and HDC in SCLC [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] allow for definitive conclusions as to the value of HGFand PBSCT-supported dose-intensified chemotherapies in this entity. The emerging evidence that superior DFS rates may also be achievable with modern forms of concurrent chemo-radiotherapy [17] [18] [19] [20] calls for a formal comparison of these two competing treatment strategies in SCLC.
Finally, two other aspects of this trial deserve mention: the occurence of secondary malignancies (SM) and the long-term survival of the cohort. With regard to the occurence of SM in our trial, it is remarkable that 4 of 15 LD-SCLC patients alive in CR at > 2 years after SDC (« = 5) or HDC (n = 10) developed a variety of secondary neoplasms (NSCLC, CML, esophageal cancer). While one of these SM has led to the death of the patient with the longest DFS (seven years) after HDC and PBSCT, both patients with secondary NSCLC under-went sucessful operations, and the patient with CML has thus far been maintained in first chronic phase with interferon.
With an incidence of 4% in the entire cohort, and of 27% in patients with a DFS > 2-year, SM are among the most important obstacles to long-term event-free survival in successfully treated SCLC. While the types of tumor are in accord with the literature on SM after SDC of SCLC [57] , and HDC in general [58] , the high incidence and the relatively favourable course of SM in our cohort are unusual. While this may represent a sampling effect, diligent and close follow-up as well as aggressive therapy of SM may have contributed to the better-than-expected outcome of patients with SM in our trial.
In conclusion, the expected historical two-year disease-free survival (DFS) of our 100 patient-cohortwith its relatively typical stage, age and PS distribution -may be estimated at 5%-7% [1, [14] [15] [16] . With a median follow-up of 38 months, DFS was 15% in our original publication [53] . The fact that overall DFS now, at a median follow-up of 68 months, is still at 14% -as a result of one patient's dying of a SM in CR -indicates, as has been observed before [14] [15] [16] , that relapse of SCLC is uncommon after a DFS of > 2 years. For this reason, and since curative treatment of relapsed SCLC is virtually impossible [16] , the prognosis of SCLC after a DFS of two years is mainly determined by comorbid medical conditions and by the occurence of SM.
Future researchers in SCLC may want to take these limiting factors into account in their trials, as new cytotoxic agents [1, 59] , and new forms of therapy [60] are incorporated into our armamentarium against the high primary aggressiveness, and powerful relapse potential of small-cell lung cancer.
